Anthera Pharmaceuticals Inc (NASDAQ:ANTH) – Investment analysts at SunTrust Banks issued their Q1 2018 earnings per share estimates for shares of Anthera Pharmaceuticals in a research report issued to clients and investors on Thursday, Zacks Investment Research reports. SunTrust Banks analyst E. Nash forecasts that the biopharmaceutical company will post earnings of ($0.68) per share for the quarter. SunTrust Banks also issued estimates for Anthera Pharmaceuticals’ Q2 2018 earnings at ($0.68) EPS, Q3 2018 earnings at ($0.67) EPS and Q4 2018 earnings at ($0.65) EPS.
Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.09.
Several other equities research analysts have also recently issued reports on ANTH. ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Monday, January 8th. Roth Capital started coverage on shares of Anthera Pharmaceuticals in a report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Anthera Pharmaceuticals in a report on Tuesday, March 6th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $4.38.
Shares of Anthera Pharmaceuticals (NASDAQ ANTH) traded down $0.02 during mid-day trading on Monday, reaching $0.46. 5,145,925 shares of the company traded hands, compared to its average volume of 4,240,000. Anthera Pharmaceuticals has a 52 week low of $0.40 and a 52 week high of $3.84. The stock has a market capitalization of $6.34, a PE ratio of -0.14 and a beta of 2.22.
Several institutional investors have recently modified their holdings of the company. Wedbush Securities Inc. boosted its stake in shares of Anthera Pharmaceuticals by 75.8% during the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 31,800 shares during the last quarter. BVF Inc. IL boosted its stake in shares of Anthera Pharmaceuticals by 20.9% during the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after acquiring an additional 209,896 shares during the last quarter. 683 Capital Management LLC purchased a new position in shares of Anthera Pharmaceuticals during the 4th quarter worth $399,000. Finally, Armistice Capital LLC purchased a new position in shares of Anthera Pharmaceuticals during the 4th quarter worth $1,269,000. Institutional investors and hedge funds own 28.12% of the company’s stock.
WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2018/03/15/anthera-pharmaceuticals-inc-anth-to-post-q1-2018-earnings-of-0-68-per-share-suntrust-banks-forecasts.html.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.